Actively Recruiting
Comparing Mocertatug Rezetecan with Bevacizumab Versus Platinum Doublet Chemotherapy with Bevacizumab for Treating Platinum-Sensitive Ovarian Cancer
Led by GlaxoSmithKline · Updated on 2026-10-01
690
Participants Needed
9
Research Sites
152 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the effectiveness and safety of mocertatug rezetecan Mo-Rez combined with bevacizumab to treat platinum-sensitive ovarian cancer. This phase 3 trial compares this combination to standard platinum doublet chemotherapy plus bevacizumab. The goal is to see if Mo-Rez with bevacizumab can shrink tumors or eliminate them and help participants live longer while understanding its side effects. Participants will be randomly assigned to one of two groups. One group will receive Mo-Rez and bevacizumab together. The other group will get standard platinum doublet chemotherapy, which includes carboplatin with paclitaxel, gemcitabine, or pegylated liposomal doxorubicin PLD, along with bevacizumab, followed by bevacizumab maintenance therapy. Treatments are given according to the study schedule, and participants will be monitored throughout the therapy. During the trial, participants will undergo regular assessments including imaging scans to measure progression-free survival and overall survival. Researchers will also track response rates, duration of response, side effects, changes in vital signs, lab tests, ECGs, and quality of life using questionnaires. The study will monitor participants for up to approximately 343 weeks to capture long-term outcomes and safety data.
CONDITIONS
Brief Title
A Study to Investigate Mocertatug Rezetecan With Bevacizumab Compared With Platinum Doublet With Bevacizumab in Participants With Platinum-sensitive Ovarian Cancer (BEHOLD-Ovarian02)
Research Team
U
US GSK Clinical Trials Call Center
E
EU GSK Clinical Trials Call Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here